Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Projektinformationen

STROBE

ID Finanzhilfevereinbarung: 672768

DOI 10.3030/672768

Projekt abgeschlossen

EK-Unterschriftsdatum 10 April 2015

Startdatum 1 Mai 2015

Enddatum 31 Oktober 2015

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

CRITICAL PHARMACEUTICALS LIMITED
United Kingdom

Ziel

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › chemical sciences › polymer sciences
• medical and health sciences › clinical medicine › ophthalmology
• medical and health sciences › medical biotechnology › cells technologies › stem cells

Programm/Programme

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

CRITICAL PHARMACEUTICALS LIMITED

• Netto-EU-Beitrag: € 50 000,00
• Adresse: BIOCITY NOTTINGHAM - PENNYFOOT STREET ; NG1 1GF NOTTINGHAM ; Vereinigtes Königreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Region: East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00